Dr. John Cush RheumNow
4 years 1 month ago
Krill Oil Effective in Knee Osteoarthritis
Krill oil supplements in knee OA was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index.
https://t.co/JkLrz5C0Pk https://t.co/XzZWXJ8zgA
A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events.
This study sought to investigate the temporal association between gout flares and cardiovascular events in a gout cohort.
Dr. John Cush RheumNow
4 years 1 month ago
Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus
Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells.
https://t.co/qOu2jMa6EK https://t.co/LMaY7gpt05
Dr. John Cush RheumNow
4 years 1 month ago
102 #RA patients in low dz activity followed for a year - half usual care vs half using smartphone assisted Pt-initiated care. DAS28 slightly increased in both groups without signif difference; app group had less visits (1.7 v 2.8; p<0.001) https://t.co/txttFjjgla https://t.co/TideQ5tVjJ
Dr. John Cush RheumNow
4 years 1 month ago
Upadacitinib in non-radiographic Axial Spondyloarthritis
The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of nr-AxSpA, extending the efficacy of UPA beyond classic ankylosing spondylitis.
https://t.co/BbvOSRxbXU https://t.co/z5QOaFKrxz
Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.
Dr. John Cush RheumNow
4 years 1 month ago
In the RECOVERY trial - 8156 hospitalized COVID-19 patients; those on baricitinib had significantly fewer deaths (12% vs 14% PBO) but the size of benefit was somewhat smaller than that suggested by previous trials. (adjusted rate ratio 0·87) https://t.co/EW7xLc9TLC https://t.co/Ahr7bwAQmJ
Dr. John Cush RheumNow
4 years 1 month ago
Risk of incident & recurrent H.Zoster higher after tofacitinib - Korean claims analysis of 11,720 seropos. RA pts Rx w/ bDMARD or tofacitinib (2011-19). 14% got HZ. Compared to other biologics (ABA), Tofa incr HZ (HR 2.5) & recurrence (HR 3.69) https://t.co/lDuqdtkIjR https://t.co/zJ3ArS3gGs
NEJM has published study results showing that vitamin D3 supplementation does not significantly lower fracture risk (vs. placebo) when used in generally healthy adults.
Dr. John Cush RheumNow
4 years 1 month ago
"He who has a strong enough why; can bear almost any how"
- Friedrich Nietzsche https://t.co/BOpO9MMijR
Dr. John Cush RheumNow
4 years 1 month ago
Upadacitinib (Rinvoq) Approved by European Commission for use in adults with active Non-Radiographic Axial Spondyloarthritis - 15 mg qd p.o. Approval based on Phase 3 SELECT-AXIS 2 nr-axSpA trial published in Lancet https://t.co/n3Pci5GyoA https://t.co/4aoSOc7xHd
Dr. John Cush RheumNow
4 years 1 month ago
QD Clinic- Still's (or Not): Fever, Joint pain & Itchy Eyes
30 yr. woman with high fevers, itchy eyes and Still's manifestations for 6 weeks.
Still's or Not?
https://t.co/kbzhCxYp7H https://t.co/FEUzdXxHoW
Dr. John Cush RheumNow
4 years 1 month ago
Not Still’s – Now What?
Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider?
https://t.co/xPXZVzTXJr https://t.co/7hmhXFh6O3
Krill oil supplements in knee osteoarthritis (OA) was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index. Krill oil, rich in anti-inflammatory long-chain (LC) omega-3 ( ω–3) PUFAs and astaxanthin, is thought to be safe and now shown to be effective nutritional treatment for mild to moderate knee OA.
Dr. John Cush RheumNow
4 years 1 month ago
Approach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing ILD in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
https://t.co/MLBGL2ZqTk https://t.co/cdO2nHAK6h

